ECM-Delivered Bioactive Renal Cells for Kidney Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for chronic kidney disease (CKD) are inadequate in preventing or reversing the progression of the disease, and there is a need for effective interventions to improve kidney function and delay the onset of end-stage renal disease.
Innovation Solution
The use of bioactive renal cell populations, formulated in a biomaterial such as a gelatin-based hydrogel, is injected into the renal cortex of patients with CKD through minimally invasive procedures to enhance kidney function and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard of care therapies (glycemic control, renin-angiotensin-aldosterone axis blockade) are used, then disease progression is slowed, but kidney function is not restored and progression cannot be arrested or reversed
Solution Approach 1:
The patent uses an extracellular matrix (ECM) biomaterial as an intermediary carrier to deliver bioactive renal cells to the kidney tissue. The ECM provides a supportive scaffold that facilitates cell survival, engraftment, and differentiation, enabling the cells to exert their regenerative effect on damaged kidney tissue without direct manipulation of the cells themselves.
Solution Approach 2:
The bioactive renal cells within the ECM composition are capable of self-differentiation and integration into the host kidney tissue. These cells can autonomously contribute to tissue regeneration and functional restoration without requiring continuous external intervention or support beyond the initial delivery via ECM.
2Reliability
If early therapeutic intervention is implemented, then disease progression may be prevented or delayed, but current early therapeutic approaches have not been successful
Solution Approach 1:
The patent changes the fundamental parameter of therapeutic approach from pharmacological intervention to cellular therapy delivered via ECM. This represents a paradigm shift from using drugs to modify disease progression to using bioactive cells within an ECM scaffold to actively regenerate functional kidney tissue, thereby improving therapeutic effectiveness.
Solution Approach 2:
The therapeutic composition is a composite material combining ECM biomaterial with bioactive renal cells. This composite structure provides both the structural support and biological activity needed for effective tissue regeneration, overcoming the limitations of single-component therapies.
3Productivity
If renal cell-based therapy is used, then regeneration of tissues and organs becomes achievable, but delivery and integration of cells present technical challenges
Solution Approach 1:
The ECM serves as an intermediary that simplifies the cell delivery process. Instead of requiring complex delivery systems to directly inject and position individual cells, the ECM acts as a pre-formed scaffold that can be delivered as a construct, automatically providing structural support and facilitating cell integration into the target tissue.
Solution Approach 2:
The ECM scaffold is prepared in advance with appropriate structural and biochemical properties before cell delivery. This preliminary preparation includes configuring the ECM's porosity, mechanical properties, and ligand presentation, which are optimized to support cell attachment, survival, and differentiation upon delivery to the kidney tissue.
Data Source
AI summary
The present invention concerns methods of using bioactive renal cell populations to provide regenerative effects to a native kidney for the treatment of chronic kidney disease.